Navigation Links
Cytochroma appoints Steven I. Engel as Vice President of Regulatory Affairs and Quality Assurance
Date:9/16/2008

MARKHAM, ON, Sept. 16 /PRNewswire/ - Cytochroma today announced that it has appointed Steven I. Engel, M.S., Pharm.D., as Vice President, Regulatory Affairs and Quality Assurance. Dr. Engel brings to Cytochroma over 20 years of experience in regulatory affairs and quality assurance, and will be responsible for directing all of Cytochroma's regulatory activities, as well as ensuring that the Company has appropriate quality systems in place. He will be based in Cytochroma's Illinois office.

"Cytochroma's activities in the areas of clinical and regulatory affairs are increasing significantly as we advance three lead product candidates through clinical development," stated Charles W. Bishop, Ph.D., Cytochroma's President and CEO. "For this reason, we have named Dr. Joel Melnick as Vice President, Clinical Research and Development and assigned his former responsibilities in the areas of regulatory affairs and quality assurance to Dr. Steve Engel. Steve has a proven track record of successful new drug registrations and post-marketing support, and we are pleased to have an individual of this caliber helping us secure global regulatory approvals for our products."

Prior to joining Cytochroma, Dr. Engel was Vice President of Regulatory Affairs and Clinical Quality Compliance at Par Pharmaceutical, Inc. where he was responsible for the regulatory strategies of both branded and generic pharmaceutical programs. Prior to joining Par Pharmaceutical, Dr. Engel held regulatory positions at AlgoRx Pharmaceuticals, Vertex Pharmaceuticals, Baxter Healthcare, Abbott Laboratories, Otsuka America Pharmaceuticals, G.D. Searle, and American Cyanamid. He earned his Doctor of Pharmacy degree from the University of Florida, his Master of Science in Pharmacology from the University of North Carolina at Chapel Hill, and his Bachelor's degrees in Pharmacy and Biology from Drake University.

"Cytochroma's portfolio of therapies for chronic kidney disease has tremendous potential," stated Dr. Engel. "I look forward to working with such a skilled team to create a leading specialty pharmaceutical company."

Cytochroma has a diverse portfolio of vitamin D-based therapeutics designed to treat disorders related to abnormal or insufficient vitamin D metabolism in chronic kidney disease (CKD) patients. These new products will address target markets that are expected to grow significantly, reaching more than $1.4 billion annually by 2013 in the U.S. alone. Cytochroma has three product candidates in development for CKD patients: CTA018 and CTAP201 are being developed for the treatment of secondary hyperparathyroidism (SHPT), while CTAP101 is being developed for the treatment of vitamin D insufficiency.

About Cytochroma

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and SHPT associated with CKD. The Company's vitamin D-based therapeutics are designed to safely and effectively treat patients with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat hyperphosphatemia in these same patients.

For more information, please visit http://www.cytochroma.com.


'/>"/>
SOURCE Cytochroma
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia
2. Cytochroma Closes $45 Million Series C Financing
3. Cytochroma Appoints R. Richard Wieland II As CFO
4. Cytochroma opens U.S. headquarters in Illinois
5. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
6. Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
7. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
8. China Yingxia International, Inc. Appoints New Vice President of Finance
9. SoluBest Appoints Michael Sheckler, MBA, as CEO
10. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
11. Affitech Appoints Dr. Keith McCullagh as Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):